Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study Identifier:
ALXN1210-PNH-201
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Ravulizumab
Date
Jan 2016 - Feb 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Ravulizumab
Date
Jan 2016 - Feb 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of multiple intravenous (IV) doses of ravulizumab administered to complement inhibitor treatment-naïve participants with PNH.
Trial Locations
Location
Status
Location
Clinical Trial Site
Toronto, Ontario, Canada, M4N 3M5
Status
N/A
Location
Clinical Trial Site
Lyon, Pierre-Bénite, France, 69495
Status
N/A
Location
Clinical Trial Site
Lille, France, 59037
Status
N/A
Location
Clinical Trial Site
Paris, France, 75475
Status
N/A
Location
Clinical Trial Site
Ulm, Baden Wuerttemberg, Germany, 89081
Status
N/A
Location
Clinical Trial Site
Aachen, Nordrhein Westfalen, Germany, 52074
Status
N/A